Ποια είναι η τιμή για Metagenomi, Inc. Common Stock (MGX)

Η τιμή για Metagenomi, Inc. Common Stock (MGX) είναι $1.21

Ποια είναι η κεφαλαιοποίηση αγοράς για Metagenomi, Inc. Common Stock (MGX)

Η κεφαλαιοποίηση αγοράς για Metagenomi, Inc. Common Stock (MGX) είναι $45.55M

Metagenomi, Inc. Common Stock (MGX) Τιμή και Κεφαλαιοποίηση Αγοράς

Metagenomi, Inc. operates as a biotechnology company focused on gene editing, committed to developing therapeutic solutions for patients. The company utilizes a distinctive genome editing toolkit, sourced from metagenomics, for its development efforts within the United States. This advanced toolkit comprises programmable nucleases, base editors, and sophisticated RNA and DNA-mediated integration systems, notably prime editing and CRISPR-associated transposases. Metagenomi has established several key collaborations: a strategic alliance with ModernaTX, Inc. to explore new genome editing systems for in vivo human therapeutic applications; a development and licensing agreement with Affini-T Therapeutics, Inc. to create and commercialize gene-edited T-cell receptor therapies for human cancer; and a partnership with Ionis Pharmaceuticals, Inc. to research, develop, and market investigational medicines leveraging genome editing technologies. Founded in 2016, the company is based in Emeryville, California.

Η τιμή για MGX	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$139,635 $45.55M	NVDA	$5.257T	+11,540,904.48%
$122,151 $45.55M	AAPL	$4.599T	+10,095,879.35%
$109,081 $45.55M	GOOG	$4.107T	+9,015,580.80%
$95,020.45 $45.55M	MSFT	$3.577T	+7,853,478.82%
$74,568.78 $45.55M	AMZN	$2.807T	+6,163,118.37%

Η τιμή για MGX

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$139,635 $45.55M